EMA panel backs EU approval of Roche’s Ocrevus for pediatric relapsing MS patients 10+

EMA’s CHMP recommended EU approval of Roche’s Ocrevus IV for relapsing multiple sclerosis in patients aged 10 and older. European Commission decision expected soon; FDA cleared the pediatric use in May 2026. Phase III OPERETTA 2 showed non-inferior relapse control versus fingolimod; 48% lower relapse risk. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via (Ref. ID: 202609180645OMX_____CNEWS_EN_GNW1001263433_en) on September 18, 2026, and is solely responsible for the information contained therein. (C)